
    
      This is a pilot, open-label, dose-response study in patients with SMA type II or III. All
      patients will be treated at each dose of once daily celecoxib (40, 80 and 160 mcg/kg) for a
      period of two weeks, for a total of 6 weeks (42 days) of treatment.
    
  